Department of Integrative Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, BC, Canada.
Department of Integrative Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
EBioMedicine. 2017 Aug;22:2-9. doi: 10.1016/j.ebiom.2017.05.027. Epub 2017 May 27.
Emerging evidence indicates that nuclear factor I/B (NFIB), a transcription factor required for proper development and regulation of cellular differentiation in several tissues, also plays critical roles in cancer. Despite being a metastatic driver in small cell lung cancer and melanoma, it has become apparent that NFIB also exhibits tumour suppressive functions in many malignancies. The contradictory contributions of NFIB to both the inhibition and promotion of tumour development and progression, corroborates its diverse and context-dependent roles in many tissues and cell types. Considering the frequent involvement of NFIB in cancer, a better understanding of its multifaceted nature may ultimately benefit the development of novel strategies for the management of a broad spectrum of malignancies. Here we discuss recent findings which bring to light NFIB as a crucial and paradoxical player in cancer.
新兴证据表明，核因子 I/B（NFIB）是一种转录因子，在几种组织的细胞分化的正常发育和调节中必不可少，它在癌症中也起着关键作用。尽管 NFIB 是小细胞肺癌和黑色素瘤的转移驱动因子，但它在许多恶性肿瘤中也表现出肿瘤抑制功能，这一点已经很明显了。NFIB 对肿瘤发生和发展的抑制和促进作用的矛盾贡献，证实了它在许多组织和细胞类型中具有多样化和依赖于背景的作用。鉴于 NFIB 经常参与癌症，更好地了解其多方面的性质可能最终有利于开发治疗广泛恶性肿瘤的新策略。在这里，我们讨论了最近的发现，这些发现揭示了 NFIB 是癌症中一个至关重要且矛盾的参与者。
